Gonzalez David Angulo Acquires 20,000 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) Stock

SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average cost of $1.37 per share, for a total transaction of $27,400.00. Following the completion of the purchase, the chief executive officer now owns 507,871 shares in the company, valued at approximately $695,783.27. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

SCYNEXIS Stock Performance

Shares of SCYX opened at $1.57 on Thursday. The firm has a market capitalization of $59.31 million, a P/E ratio of 0.77 and a beta of 1.50. SCYNEXIS, Inc. has a 52 week low of $1.26 and a 52 week high of $3.66. The stock has a 50 day moving average price of $1.78 and a two-hundred day moving average price of $1.82.

SCYNEXIS (NASDAQ:SCYX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.11). SCYNEXIS had a negative net margin of 366.09% and a negative return on equity of 57.41%. The company had revenue of $0.74 million for the quarter. On average, equities analysts forecast that SCYNEXIS, Inc. will post -0.68 earnings per share for the current year.

Analyst Ratings Changes

Separately, StockNews.com downgraded SCYNEXIS from a “hold” rating to a “sell” rating in a report on Monday, August 12th.

Institutional Investors Weigh In On SCYNEXIS

Several institutional investors and hedge funds have recently added to or reduced their stakes in SCYX. Decheng Capital LLC purchased a new position in shares of SCYNEXIS in the 4th quarter worth approximately $1,239,000. Empowered Funds LLC grew its stake in SCYNEXIS by 8.1% in the 1st quarter. Empowered Funds LLC now owns 88,414 shares of the company’s stock valued at $130,000 after purchasing an additional 6,650 shares during the period. D.A. Davidson & CO. increased its position in shares of SCYNEXIS by 8.3% during the 4th quarter. D.A. Davidson & CO. now owns 526,490 shares of the company’s stock valued at $1,174,000 after purchasing an additional 40,164 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of SCYNEXIS by 5.4% during the 1st quarter. Acadian Asset Management LLC now owns 421,083 shares of the company’s stock valued at $618,000 after purchasing an additional 21,700 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of SCYNEXIS by 8.3% during the 1st quarter. Vanguard Group Inc. now owns 1,687,670 shares of the company’s stock worth $2,481,000 after purchasing an additional 129,153 shares during the period. Hedge funds and other institutional investors own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.